Prediction Model for Early-Stage Pancreatic Cancer Using Routinely Measured Blood Biomarkers
Lenka N.C. Boyd(Amsterdam University Medical Centers), Geert Kazemier(European Organisation for Research and Treatment of Cancer), Laura L. Meijer(Erasmus MC), Tessa Y. S. Le Large(Amsterdam University Medical Centers), Hanneke W.M. van Laarhoven(Dutch Cancer Society), Mahsoem Ali(Amsterdam Neuroscience), Elisa Giovannetti(University of Pisa), Jisce R. Puik(Amsterdam UMC Location Vrije Universiteit Amsterdam), Laura Kam(Amsterdam UMC Location Vrije Universiteit Amsterdam), Ingrid Garajová(University of Parma), Stephanie M. Fraga Rodrigues(Amsterdam UMC Location Vrije Universiteit Amsterdam), Adam E. Frampton(Hammersmith Hospital), Marc G. Besselink(Amsterdam Neuroscience), Annalisa Comandatore(University of Pisa), Luca Morelli(University of Pisa)
Cited by 17
Related Papers
Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial
|The Lancet Oncology|2015|2.6k
Preoperative Chemoradiotherapy Versus Immediate Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Results of the Dutch Randomized Phase III PREOPANC Trial
|Journal of Clinical Oncology|2020|1.1k
Endoscopic Transgastric vs Surgical Necrosectomy for Infected Necrotizing Pancreatitis
|JAMA|2012|735
Endoscopic or surgical step-up approach for infected necrotising pancreatitis: a multicentre randomised trial
|The Lancet|2017|715
United European Gastroenterology evidence‐based guidelines for the diagnosis and therapy of chronic pancreatitis (HaPanEU)
|United European Gastroenterology Journal|2017|698